PharmaVoice Logo

Healthcare Leaders Hub

Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline

PharmaShots

Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline

Shots: Eli Lilly has entered into a definitive agreement to acquire Calytrix Bio; Calytrix shareholders could receive up to $1.5B in cash, incl. an upfront payment & subsequent clinical & regulatory milestones The acquisition adds Calytrix’s lead preclinical biparatopic antibody, which targets both Type 1 & Type 2 mutant calreticulin (mCALR) for mCALR-driven essential thrombocythemia… The post Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline appeared first on PharmaShots.

Read Full Article
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

Pharma Tech

J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

The deal sees J&J bolster its pipeline with a bispecific antibody in Phase III development for wAMD and DME.

Read Full Article
Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline

PharmaShots

Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline

Shots: Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2B upfront, with potential regulatory & commercial milestones of up to ~$1.125B; closing is expected before the end of 2026 The acquisition adds OLN324, a P-III VEGF/Ang2 bispecific antibody with high Ang2 potency & a small minibody format, being developed… The post Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline appeared first on PharmaShots.

Read Full Article
RevMed CEO on tackling “complex” launch for wonder pancreatic drug

Pharma Tech

RevMed CEO on tackling “complex” launch for wonder pancreatic drug

One of oncology’s biggest success stories this year, RevMed's Rasonque, has started with strong uptake in the US.

Read Full Article
Flagship Pioneering expands to UK with £100m AI-native lab 

Pharma Tech

Flagship Pioneering expands to UK with £100m AI-native lab 

Flagship's UK investment marks another sign of turning tides for the UK life sciences sector, following prior big pharma funding pullouts.

Read Full Article

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

PharmaShots

Nov 16, 2026, 11:25 PM

Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline

Shots: Eli Lilly has entered into a definitive agreement to acquire Calytrix Bio; Calytrix shareholders could receive up to $1.5B in cash, incl. an upfront payment & subsequent clinical & regulatory milestones The acquisition adds Calytrix’s lead preclinical biparatopic antibody, which targets both Type 1 & Type 2 mutant calreticulin (mCALR) for mCALR-driven essential thrombocythemia… The post Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline appeared first on PharmaShots.

Pharma Tech

Nov 16, 2026, 5:03 PM

J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

The deal sees J&J bolster its pipeline with a bispecific antibody in Phase III development for wAMD and DME.

PharmaShots

Nov 16, 2026, 4:47 PM

Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline

Shots: Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2B upfront, with potential regulatory & commercial milestones of up to ~$1.125B; closing is expected before the end of 2026 The acquisition adds OLN324, a P-III VEGF/Ang2 bispecific antibody with high Ang2 potency & a small minibody format, being developed… The post Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline appeared first on PharmaShots.

Pharma Tech

Nov 16, 2026, 4:15 PM

RevMed CEO on tackling “complex” launch for wonder pancreatic drug

One of oncology’s biggest success stories this year, RevMed's Rasonque, has started with strong uptake in the US.

Pharma Tech

Nov 16, 2026, 4:01 PM

Flagship Pioneering expands to UK with £100m AI-native lab 

Flagship's UK investment marks another sign of turning tides for the UK life sciences sector, following prior big pharma funding pullouts.

PharmaShots

Nov 16, 2026, 11:49 AM

Seawolf Therapeutics Debuts with $100M and Enters into an Up to $1.2B Collaboration with Sanofi to Develop DNA Medicines

Shots: Seawolf Therapeutics has emerged from stealth with $100M, comprising a seed round led by Versant Ventures & a Series A from Versant, MPM BioImpact & Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Alexandria Venture Investments, Pathway to Cures & others Seawolf also entered into a multi-target research collaboration & exclusive license… The post Seawolf Therapeutics Debuts with $100M and Enters into an Up to $1.2B Collaboration with Sanofi to Develop DNA Medicines appeared first on PharmaShots.

News

Latest industry coverage

Google News

Nov 16, 2026, 11:15 PM

Study Finds Drug Repurposing Widely Endorsed for Rare Diseases Despite Commercial Hurdles - Bioengineer.org

Study Finds Drug Repurposing Widely Endorsed for Rare Diseases Despite Commercial Hurdles  Bioengineer.org

Google News

Nov 16, 2026, 10:33 PM

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain - Reuters

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain  Reuters

Google News

Nov 16, 2026, 10:33 PM

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain - CNA

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain  CNA

Google News

Nov 16, 2026, 10:27 PM

LEO Pharma owners see market conditions as unsuitable for IPO, CEO says - Reuters

LEO Pharma owners see market conditions as unsuitable for IPO, CEO says  Reuters

Google News

Nov 16, 2026, 8:37 PM

Trust during turbulence – how does the pharmaceutical industry respond to the challenge of misinformation? - The Association of the British Pharmaceutical Industry

Trust during turbulence – how does the pharmaceutical industry respond to the challenge of misinformation?  The Association of the British Pharmaceutical Industry

Google News

Nov 16, 2026, 7:53 PM

Mankind licenses Lung cancer drug ensartinib from China’s Betta Pharmaceuticals - pharma.economictimes.indiatimes.com

Mankind licenses Lung cancer drug ensartinib from China’s Betta Pharmaceuticals  pharma.economictimes.indiatimes.com

Google News

Nov 16, 2026, 7:16 PM

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain - TradingView

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain  TradingView

Google News

Nov 16, 2026, 6:51 PM

Sofinnova Partners backs European life sciences sector with €725M raise - Pharmaceutical Technology

Sofinnova Partners backs European life sciences sector with €725M raise  Pharmaceutical Technology

Google News

Nov 16, 2026, 6:21 PM

Expert warns of battleground over global access to newer GLP-1 drugs for obesity - STAT

Expert warns of battleground over global access to newer GLP-1 drugs for obesity  STAT

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer